←
GSK US11,123 posts
GSK US avatar

GSK US

@GSKUS

We are uniting science, technology and talent to get ahead of disease together. Our community guidelines: gsk.to/socialmedia

◷ Joined March 2009▧ 3,821 Photos and videos
GSK US avatar
GSK US@GSKUS·22h

#News for #investors and #media: Today, we announced that the US Food and Drug Administration (FDA) granted approval for one of our therapies to treat adults with advanced ALK-positive non-small cell lung cancer. Learn more: gsk.to/4CacNpT

0:07
GSK US avatar
GSK US@GSKUS·Nov 5

#News for #Investors and #Media: At #TLM26 we’re unveiling our latest advancements across our hepatology pipeline for chronic hepatitis B (CHB), metabolic dysfunction-associated steatohepatitis (MASH), and alcohol-related liver disease (ALD). Find out more in the press release: gsk.to/4egVmcZ #TLM26

0:07
GSK US avatar
GSK US@GSKUS·Oct 20

#News for #Investors and #Media: Today @US_FDA has approved our first-in-class treatment for chronic hepatitis B (CHB). This approval reflects our commitment to innovation in liver disease, where significant unmet need remains. Learn more: gsk.to/4z5NgfC

0:07
GSK US avatar
GSK US@GSKUS·Oct 19

#News for #Investors and #Media: The US Food and Drug Administration (FDA) has approved a new indication for one of our immunotherapies. Read more: gsk.to/4zCl4Rf

0:07
GSK US avatar
GSK US@GSKUS·Aug 24

#News for #Investors and #Media: Today, we announced the US FDA accepted the application for one of our immuno-oncology therapies for priority review. Learn more: gsk.to/4gO7q71

0:07
GSK avatar
⟳ GSK US retweeted
GSK@GSK·Jul 28

Today, we’re announcing a £400 million investment in UK life sciences, including plans to establish a new flagship R&D centre in Cambridge. The new site on the city’s Biomedical Campus, one of the world’s leading life sciences ecosystems, will be a catalyst to fuel collaboration and accelerate GSK R&D.

0:54
GSK avatar
⟳ GSK US retweeted
GSK@GSK·Jul 28

News for #Investors and #Media Watch our CEO Luke Miels as he shares our strong Q2 core performance, continued momentum and plans to accelerate our R&D, including a new flagship R&D centre in Cambridge. Find out more: gsk.to/4pG56BQ #Q2Results $GSK

1:37
GSK avatar
⟳ GSK US retweeted
GSK@GSK·Jul 21

#News for #Investors and #Media: We’ll be at #AIDS2026 with @ViiVHC, our specialist HIV company, presenting research and insights from our innovative portfolio and integrase strand transfer inhibitor (INSTI)-powered pipeline. Find out more in the press release: gsk.to/4fdROcs Our mission: to leave no person living with HIV behind.

Post attachment
GSK US avatar
GSK US@GSKUS·Jun 17

#News for #Media and #Investors: Today @US_FDA has approved our oral anti-infective for complicated urinary tract infections (cUTIs). With three million cUTIs treated annually in the US, this approval reflects our commitment to innovation in anti-infectives. Learn more: us.gsk.com/en-us/media/press…

0:07
GSK US avatar
GSK US@GSKUS·Jun 12

#News for #Investors and #Media: Today, we announced that the US FDA has granted regulatory designations for one of our therapies for the treatment of VEXAS syndrome. Learn more: gsk.to/4eoSdHf

0:07
GSK avatar
⟳ GSK US retweeted
GSK@GSK·Jun 9

#News for #investors and #media: We have entered an agreement to acquire clinical-stage precision oncology company Nuvalent, Inc., bringing in multiple lung cancer assets to our existing oncology portfolio. Find out more: gsk.to/4ooHOjy

0:07
GSK US avatar
GSK US@GSKUS·May 15

Getting ahead of respiratory disease means relentless innovation, moving beyond just symptom management. At #ATS2026, we're sharing 33 abstracts across our respiratory portfolio. Our focus: targeting underlying drivers of conditions like asthma, COPD, and refractory chronic cough to improve patient outcomes. Explore our science – a meaningful investment for patients, health systems, and societies.

0:29